⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20387008 | 0.95 | MC4R (0.34) | — | |
| SCHEMBL1116249 | 0.83 | — | — | |
| SCHEMBL9322170 | 0.83 | ALDH1A1 (0.30) | — | |
| SCHEMBL81580 | 0.81 | MC4R (0.44) | — | |
| SCHEMBL16316010 | 0.81 | MC4R (0.44) | — | |
| SCHEMBL22753497 | 0.81 | MC4R (0.44) | — | |
| SCHEMBL26844927 | 0.81 | FDPS (0.30) | — | |
| SCHEMBL840162 | 0.81 | CHRNA7 (0.36) | — | |
| SCHEMBL27966219 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL21568420 | 0.78 | CHRNA7 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145483-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER AND METHODS OF MAKING AND USING THE SAME | HTG MOLECULAR DIAGNOSTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024077023-A2 | CEREBLON-RECRUITING BCL-XL/BCL-2 DUAL DEGRADERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230348658-A1 | COPOLYMERS AND TERPOLYMERS OF POST MODIFIED POLYACRYLATES AS EFFICIENT GAS HYDRATE INHIBITORS | SAUDI ARABIAN OIL COMPANY (SA) | 2023-11-02 | — | — | US | disclosed |
| EP-3033066-B1 | POLYUREA OR POLYURETHANE CAPSULES | INT FLAVORS & FRAGRANCES INC (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023116835-A1 | MULTI-PROTEIN DEGRADATION AGENT HAVING IMIDE SKELETON | 苏州开拓药业股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | Xeniopro GmbH (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230141913-A2 | PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERACTIVE ACTIVITY | Xeniopro GmbH (DE) | 2023-05-11 | — | — | US | disclosed |
| EP-4122499-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2023-01-25 | — | — | EP | disclosed |
| US-20220145461-A1 | RARE EARTH PRECURSOR, METHOD OF PREPARING THE SAME, AND METHOD OF FORMING THIN FILM USING THE SAME | HANSOL CHEMICAL CO., LTD. (KR) | 2022-05-12 | — | — | US | disclosed |
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7893068-B2 | Macrolide compounds comprising 18,19-epoxytricosa-8,12,14-trien-11-olide derivatives; angiogenesis inhibitors; anticarcinogenic, antimetastasis, antiinflammatory, and antitumor agents; antihypoxic agents; endothelial growth factor suppressors; retinal neovascularization, diabetic retinopathy | MERCIAN CORPORATION (JP) | 2011-02-22 | — | — | US | disclosed |
| US-7619100-B2 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7576204-B2 | Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same | MERCIAN CORPORATION (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7550503-B2 | Physiologically active substances | EISAI R& D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-20090105274-A1 | Indolecarboxylic Acid Derivative Having PGD2 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20080280288-A1 | Assay Method to Predict Sensitivity of Cancer Cell to Anticancer Drug | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-11-13 | — | — | US | disclosed |
| US-20080275059-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | KOTAKE YOSHIHIKO | 2008-11-06 | — | — | US | disclosed |
| US-20080255146-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-7256178-B2 | Physiologically active substances | EISAI CO., LTD. (JP) | 2007-08-14 | — | — | US | disclosed |